Volume Spike Investor

Dyax Corp. (NASDAQ: DYAX) is soaring after the comapny won FDA approval to market its Kalbitor for the treatment of genetic hereditary angioedema in patients 16 years and up.  This is a rare disorder caused by fluids building up outside of blood vessels and causes swelling in extremities, the face, airway, and internal organs.  This is listed as the top gainer on NASDAQ with a 27% gain at $4.46 as of 8:27 AM EST.  Shares closed at $3.50 yesterday and the 52-week trading range is $1.55 to $4.39.  We have also already seen over 1.1 million shares trade hands versus an average volume of 466K.

JON C. OGG